Literature DB >> 15046381

Evaluation of a questionnaire to assess compliance with anti-asthma medications.

Katherine M Walewski1, Lisa Cicutto, Anthony D D'Urzo, Ronald J Heslegrave, Kenneth R Chapman.   

Abstract

Compliance with anti-asthma medication is essential in controlling symptoms and exacerbations in patients with asthma. Unfortunately, not all patients adhere to their treatment regimen, and it is difficult for clinicians to estimate a patient's compliance, since there is no simple and accurate method currently available to assist in its assessment. The objective of this study was to assess the validity and accuracy of utilizing clinical information regarding a patient's prescription refill frequency, inhaler emptying rate, reported forgetfulness, and short-acting bronchodilator usage to predict daily, anti-inflammatory intake. A questionnaire based on the clinical information described above was administered verbally to asthma patients with varying disease severities. Patient responses were compared to the patient's own pharmacy records. Questions that correlated significantly with pharmacy records were subsequently fit into a multiple regression model. Out of 147 eligible participants, 70 completed the questionnaire and had comprehensive pharmacy data available. There was a significant correlation between daily anti-inflammatory intake as estimated by pharmacy records and daily anti-inflammatory intake as determined by inhaler emptying rate (p<0.05), reported forgetfulness (p<0.05), and short-acting bronchodilator usage (p<0.05). These items were fit into a multiple regression model, which was predictive of daily anti-inflammatory intake as determined by pharmacy records. The sensitivity and specificity of our regression model in detecting non-compliance was 44% and 86%, respectively. We conclude that by inquiring into a patient's inhaler emptying rate, reported forgetfulness, and short-acting bronchodilator usage, a clinician may be able to more accurately estimate a patient's daily intake of anti-inflammatory medication.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15046381     DOI: 10.1081/jas-120026064

Source DB:  PubMed          Journal:  J Asthma        ISSN: 0277-0903            Impact factor:   2.515


  6 in total

Review 1.  Asthma that is unresponsive to usual care.

Authors:  Kenneth R Chapman; Andrew McIvor
Journal:  CMAJ       Date:  2009-10-13       Impact factor: 8.262

2.  Patient-reported outcome instruments that evaluate adherence behaviours in adults with asthma: a systematic review of measurement properties.

Authors:  Myriam Gagné; Louis-Philippe Boulet; Norma Pérez; Jocelyne Moisan
Journal:  Br J Clin Pharmacol       Date:  2018-06-26       Impact factor: 4.335

3.  National asthma observational survey of severe asthmatics in Israel: the no-air study.

Authors:  Gabriel Izbicki; Anna Grosman; Zeev Weiler; Tiberiu Shulimzon; Uri Laxer; Gershon Fink
Journal:  Allergy Asthma Clin Immunol       Date:  2012-06-01       Impact factor: 3.406

4.  Development of an Item Bank to Measure Medication Adherence: Systematic Review.

Authors:  Yu Heng Kwan; Livia Jia Yi Oo; Dionne Hui Fang Loh; Truls Østbye; Lian Leng Low; Hayden Barry Bosworth; Julian Thumboo; Jie Kie Phang; Si Dun Weng; Dan V Blalock; Eng Hui Chew; Kai Zhen Yap; Corrinne Yong Koon Tan; Sungwon Yoon; Warren Fong
Journal:  J Med Internet Res       Date:  2020-10-08       Impact factor: 5.428

5.  Measurement Properties of Existing Patient-Reported Outcome Measures on Medication Adherence: Systematic Review.

Authors:  Yu Heng Kwan; Si Dun Weng; Dionne Hui Fang Loh; Truls Østbye; Lian Leng Low; Hayden Barry Bosworth; Julian Thumboo; Jie Kie Phang; Livia Jia Yi Oo; Dan V Blalock; Eng Hui Chew; Kai Zhen Yap; Corrinne Yong Koon Tan; Sungwon Yoon; Warren Fong
Journal:  J Med Internet Res       Date:  2020-10-09       Impact factor: 5.428

6.  Evaluation of Real-Life Investigational Use of Enoximone in Asthma, the Third Step in Drug Repurposing: A Preliminary Report.

Authors:  Jan Beute; Pieter Boermans; Alex KleinJan
Journal:  Can Respir J       Date:  2021-11-01       Impact factor: 2.409

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.